Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
about
Potential of apoptotic pathway-targeted cancer therapeutic research: Where do we stand?Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cellsGetting TRAIL back on track for cancer therapyRole of nanotechnology and gene delivery systems in TRAIL-based therapiesHyperthermia enhances mapatumumab-induced apoptotic death through ubiquitin-mediated degradation of cellular FLIP(long) in human colon cancer cellsPTHrP Overexpression Increases Sensitivity of Breast Cancer Cells to Apo2L/TRAIL.Eculizumab hepatotoxicity in pediatric aHUS.Antibody phage display libraries: contributions to oncology.A Phase 1b/2 trial of mapatumumab in patients with relapsed/refractory non-Hodgkin's lymphoma.Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 ExpressionMicrosatellite instability, KRAS mutations and cellular distribution of TRAIL-receptors in early stage colorectal cancer.Loss of TRAIL-receptors is a recurrent feature in pancreatic cancer and determines the prognosis of patients with no nodal metastasis after surgery.Evidence for two modes of synergistic induction of apoptosis by mapatumumab and oxaliplatin in combination with hyperthermia in human colon cancer cells.A New Player in the Development of TRAIL Based Therapies for Hepatocarcinoma Treatment: ATM Kinase.Identification of TRAIL-inducing compounds highlights small molecule ONC201/TIC10 as a unique anti-cancer agent that activates the TRAIL pathwayAdvances in phage display technology for drug discovery.TRAIL-receptor preferences in pancreatic cancer cells revisited: Both TRAIL-R1 and TRAIL-R2 have a licence to kill.Dual inactivation of Akt and ERK by TIC10 signals Foxo3a nuclear translocation, TRAIL gene induction, and potent antitumor effects.DR4 specific TRAIL variants are more efficacious than wild-type TRAIL in pancreatic cancer.Intracellular-signaling tumor-regression modeling of the pro-apoptotic receptor agonists dulanermin and conatumumab.Delivery of tumor-homing TRAIL sensitizer with long-acting TRAIL as a therapy for TRAIL-resistant tumors.The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and AxlClinical targeting of the TNF and TNFR superfamiliesTNFRSF10C copy number variation is associated with metastatic colorectal cancer.TRAIL-receptor 1 IgM antibodies strongly induce apoptosis in human cancer cells in vitro and in vivo.Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death receptors.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapyDelivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effectsTherapeutic applications of TRAIL receptor agonists in cancer and beyond.An optimized antibody-single-chain TRAIL fusion protein for cancer therapy.hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma.TRAIL receptor signaling and therapeutics.Towards novel paradigms for cancer therapy.Radioimmunotherapy of solid tumors: searching for the right target.Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders.Harnessing the cell death pathway for targeted cancer treatment.Recent advances in the application of antibodies as therapeutics.TRAIL receptor signaling and therapeutic option in bone tumors: the trap of the bone microenvironment.Emerging drugs for cervical cancer.Apoptosis-modulating drugs for improved cancer therapy.
P2860
Q26771601-1BB2A641-629E-4C74-A817-795283CAD4B1Q26852287-7FB881C9-B8F1-49B5-9EA4-B7D456A54B60Q27027460-8F372B72-C8F6-40DB-955A-F08B981562E8Q28076798-267B88C3-F44B-4C9C-BC60-A0B8AB13438CQ28397571-4F13BBF4-3F02-42DC-99E1-652209ADF6BBQ31122542-3EA0E048-7163-4308-87F0-B5235CAF4AE6Q33418797-29F16D20-BCD9-4A15-85E7-3536137F5166Q34323991-0B17C596-5F92-4DC9-B4BE-33AB2A3E05CEQ34433792-FD441800-D4BC-4B8D-A684-CEE6CE140366Q34464915-771B0614-CC61-48DF-B656-D7228C56A732Q34532108-B8E212B2-3C39-4A7A-B1A9-9D5077BADE57Q34608366-69BE8CC3-14C0-453F-A46B-076498842AACQ34980866-0109C758-E4D1-423F-BDF8-B97F9A5A4DDBQ35038107-9CDF0E2B-3C0D-485B-AFF3-30B9FA519F6BQ35595688-3B24F696-3EA8-46C7-A145-F116EE2BB7E9Q35614190-0F93C111-96BC-4580-888B-8C89B9E88105Q35681794-5E7C2CB5-E5E4-4918-AE35-CE51FBB7FDBCQ35951059-F23A1C50-3BC0-4D3A-9CCE-9A7B6C571DCDQ36215003-569E9C9F-7FC7-406E-BD19-70DF8F5D63CFQ36366424-8EA11C56-41A4-485E-A121-C61A10BA5EB7Q36395984-3F36313C-0CAE-4808-B84E-382CBD40D85FQ36580632-D6E1E8FD-A922-4A69-9FA0-5223FFB68184Q36762882-A8814FDD-42D9-4843-BAFB-E37385329798Q36936939-5074B85F-A1A9-4EDB-A335-105CF290E319Q37012681-E0495AD2-DC97-48CC-B79F-96535C736D21Q37063421-EFDE89DE-AD39-41FA-A25B-800B73A88455Q37071019-D20DA745-5949-4253-8D22-700A5C71F8C7Q37073589-3B71773A-63FE-4D81-9F36-B546FAA07DB1Q37114025-ACB2A8C7-4AE3-42D0-A258-30D58B95F368Q37141627-80CF8394-791C-4D7D-9C93-7B421F3B080FQ37492231-D4D72DEE-D724-460A-9805-D922FBFB65B9Q37785559-BA12D526-3931-482A-9F92-CAE882D624E5Q37799251-AF14157F-22F3-4997-99D3-9816A57B8CC3Q37804904-183539E4-DAE6-4595-9801-F5322BEC46FCQ37913356-E0019328-150A-4BEB-AC8F-8EB1FC363730Q37942090-624604E1-198E-4163-A671-6ADAD937E3EFQ37968255-6E3BD759-5C6E-4DEF-BDC8-6703268B0FC6Q37972139-A2EF728C-59D8-46FC-8E39-8151FBD80D38Q38005222-C992C51E-8EF7-4BDB-BA38-35A05DC2D16FQ38005914-E370C40E-69A9-49E7-9242-E13541DF4411
P2860
Phase II trial of mapatumumab, a fully human agonistic monoclonal antibody that targets and activates the tumour necrosis factor apoptosis-inducing ligand receptor-1 (TRAIL-R1), in patients with refractory colorectal cancer
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase II trial of mapatumumab, ...... h refractory colorectal cancer
@ast
Phase II trial of mapatumumab, ...... h refractory colorectal cancer
@en
type
label
Phase II trial of mapatumumab, ...... h refractory colorectal cancer
@ast
Phase II trial of mapatumumab, ...... h refractory colorectal cancer
@en
prefLabel
Phase II trial of mapatumumab, ...... h refractory colorectal cancer
@ast
Phase II trial of mapatumumab, ...... h refractory colorectal cancer
@en
P2093
P2860
P921
P356
P1476
Phase II trial of mapatumumab, ...... h refractory colorectal cancer
@en
P2093
M Przyborek
T Trarbach
V Heinemann
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605507
P407
P577
2010-01-12T00:00:00Z
P5875
P6179
1018087521